Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wheelchair advocates fail to win an injunction

This article was originally published in The Gray Sheet

Executive Summary

CMS interim final rule that changes the method of prescribing and paying for power mobility devices became effective Oct. 25, after a D.C. federal district judge decided not to award the temporary injunction sought by industry stakeholders. The Power Mobility Coalition (PMC), a national association of wheelchair stakeholders, said it would continue working with CMS after the judge indicated he did not think the group had met the jurisdictional hurdle to obtain an injunction. PMC said it expects the judge to release a written opinion within the next two weeks. The interim final rule, "Conditions for Payment of Power Mobility Devices," establishes a method of prescription based on documents from a patient's medical history, replacing the previously used certificate of medical necessity...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT022850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel